Purpose: To search for new predictive breast cancer biomarkers. We analyzed the serum concentrations of biomarkers involved in carcinogenesis, which can also be targeted by therapy. Methods: In a single-center prospective study, the serum levels of Aurora A, thymidine kinase 1, and human epidermal growth factor receptor type 3 (HER3) were determined in 119 women with BC before neoadjuvant treatment using ELISA kits. Results: The following clinical data were analyzed: age; TNM; the expression of ER, PGR, HER2, and Ki67; histological grade (G); and the response to neoadjuvant treatment (NAT) in the residual tumor burden classification (RCB). A complete pathological response (pCR) was achieved after NAT in 41 patients (34%). The highest proportion of the patients with a confirmed pCR was found for triple negative breast cancer (TNBC) (62.5%); non-luminal HER2-positive (52.6%) cancer subtypes (p= 0.0003); and in the G3 group (50%;p= 0.0078). The patients with higher levels of Aurora A were more likely to achieve pCR (p= 0.039). In the multivariate analysis, the serum Aurora A levels ≥ 4.75 ng/mL correlated with a higher rate of pCR (OR: 3.5; 95% CI: 1.2–10.1;p= 0.023). Conclusions: We showed that in a biologically heterogeneous group of BC patients, the pretreatment serum Aurora A levels were of significant value in predicting the response to NAT.
目的：探索新的乳腺癌预测性生物标志物。本研究分析了参与癌变过程且可作为治疗靶点的生物标志物血清浓度。方法：在一项单中心前瞻性研究中，采用酶联免疫吸附测定试剂盒检测了119例乳腺癌患者新辅助治疗前血清中极光激酶A、胸苷激酶1及人表皮生长因子受体3（HER3）的水平。结果：分析了以下临床数据：年龄、TNM分期、雌激素受体（ER）、孕激素受体（PGR）、HER2及Ki67表达状态、组织学分级（G），以及新辅助治疗后残余肿瘤负荷分级（RCB）中的治疗反应。41例患者（34%）在新辅助治疗后达到病理完全缓解（pCR）。在三阴性乳腺癌（62.5%）、非腔面型HER2阳性亚型（52.6%）（p=0.0003）及G3分级组（50%；p=0.0078）中观察到最高比例的pCR患者。极光激酶A水平较高的患者更易获得pCR（p=0.039）。多变量分析显示，血清极光激酶A水平≥4.75 ng/mL与更高的pCR率相关（比值比：3.5；95%置信区间：1.2–10.1；p=0.023）。结论：本研究证实，在生物学异质性的乳腺癌患者群体中，治疗前血清极光激酶A水平对预测新辅助治疗反应具有重要价值。
肿瘤(癌症)患者之家